• About us
• Contact

Advertisement

Collaboration › Details

CRISPR Therapeutics–Bank of America: investor conference, 202005 supply service CRISPR Tx presents at BofA Securities 2020 Health Care Conference

 

	Period	2020-05-14
	Partner, 1st	CRISPR Therapeutics AG (Nasdaq: CRSP)
	Group	CRISPR Therapeutics (Group)
	Partner, 2nd	Bank of America Securities LLC (BofA Securities)
	Group	Bank of America (BofA) (Group)
	Product	Bank of America Merrill Lynch Global Healthcare Conference 2020 DIGITAL (Las Vegas)
	Product 2	CRISPR-based therapeutic
	Person	Kulkarni, Samarth (Sam) (CRISPR Therapeutics 201712– promoted CEO before CBO)
	Person 2	Kim, Susan (CRISPR Therapeutics 201809 Investor Relations)

CRISPR Therapeutics AG. (5/7/20). "Press Release: CRISPR Therapeutics to Present at the Bank of America Securities 2020 Health Care Conference". Zug & Cambridge, MA.

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics, is scheduled to present at the virtual Bank of America Securities 2020 Health Care Conference on Thursday, May 14, 2020, at 11:40 a.m. ET.

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.


About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc.CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.


Investor Contact:
Susan Kim
susan.kim@crisprtx.com

Media Contact:
Rachel Eides
WCG on behalf of CRISPR
617-337-4167
reides@wcgworld.com

Record changed: 2020-05-11

Advertisement

More documents for CRISPR Therapeutics (Group)

• [1] CRISPR Therapeutics AG. (2/13/24). "Press Release: CRISPR Therapeutics Announces $280 Million Registered Direct Offering". Zug & Boston, MA....
• [2] CRISPR Therapeutics AG. (2/13/24). "Press Release: European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, Casgevy (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)". Z...
• [3] CRISPR Therapeutics AG. (1/3/24). "Press Release: CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference". Zug & Boston, MA....
• [4] CRISPR Therapeutics AG. (6/13/23). "Pressemitteilung: CRISPR Therapeutics to Participate in Goldman Sachs 44th Annual Global Healthcare Conference". Zug & Cambridge, MA....
• [5] CRISPR Therapeutics AG. (4/13/23). "Press Release: CRISPR Therapeutics to Participate in Needham’s 22nd Annual Healthcare Conference". Zug & Cambridge, MA....
• [6] CRISPR Therapeutics AG. (4/3/23). "Press Release: CRISPR Therapeutics and Vertex Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for Exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalas...
• [7] CRISPR Therapeutics AG. (3/29/23). "Press Release: CRISPR Therapeutics Announces Departure of Board Member". Zug & Boston, MA....
• [8] CRISPR Therapeutics AG. (3/27/23). "Press Release: CRISPR Therapeutics and Vertex Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes". Boston, MA & Zug....
• [9] CRISPR Therapeutics AG. (3/13/23). "Press Release: CRISPR Therapeutics Announces Transition of Chief Financial Officer". Zug & Boston, MA....
• [10] CRISPR Therapeutics AG. (2/27/23). "Press Release: CRISPR Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference". Zug & Boston, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.